13F Filings History of Martin Capital Partners, LLC

Latest 13F report
Q4 2025 - 06 Jan 2026
Value $
$265,833,000
Signature - Title
Ryan Adair - Operations Manager
Location
Eugene, OR
Summary
This page shows a list of all the recent 13F filings made by Martin Capital Partners, LLC. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Martin Capital Partners, LLC reported 70 stock holdings with total value $265,833,000 as of Q4 2025. Top holdings included AMGN, MSFT, ASML, CSCO, and CFR.

Notify me when Martin Capital Partners, LLC files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 70 $265,833,000 +$22,670,371 -$17,870,764 +$4,799,607 AMGN, MSFT, ASML, CSCO, CFR 13F-HR 06 Jan 2026, 10:28
Q3 2025 70 $257,801,000 +$22,975,164 -$26,504,543 -$3,529,379 AMGN, CME, CFR, ASML, MSFT 13F-HR 03 Oct 2025, 17:56
Q2 2025 75 $255,075,000 +$172,287,186 -$224,000 +$172,063,186 JPM, CME, CFR, AMGN, ETR 13F-HR 08 Jul 2025, 13:54
Q1 2025 58 $83,618,000 +$3,340,618 -$5,894,200 -$2,553,582 SPSB, IGSB, AMGN, JPM, ETR 13F-HR 15 Apr 2025, 13:49
Q4 2024 58 $84,293,000 +$6,137,000 -$111,109,387 -$104,972,387 SPSB, IGSB, CFR, JPM, SHY 13F-HR 27 Jan 2025, 12:17
Q3 2024 69 $202,380,000 +$7,323,821 -$69,182,684 -$61,858,863 ETR, AMGN, VZ, TXN, CFR 13F-HR 15 Oct 2024, 10:23
Q2 2024 71 $247,575,000 +$1,863,504 -$8,324,124 -$6,460,620 UL, GD, AMGN, TXN, JPM 13F-HR 15 Jul 2024, 14:33
Q1 2024 69 $260,749,000 +$16,303,377 -$12,564,516 +$3,738,861 MRK, GD, CFR, UL, VZ 13F-HR 05 Apr 2024, 14:03
Q4 2023 70 $245,307,000 +$11,213,293 -$18,074,224 -$6,860,931 JPM, AMGN, CFR, GD, MSM 13F-HR 05 Jan 2024, 18:41
Q3 2023 72 $237,633,000 +$4,428,334 -$5,504,979 -$1,076,645 JPM, UL, AMGN, MSM, CMCSA 13F-HR 13 Oct 2023, 13:14
Q2 2023 72 $246,281,000 +$13,167,100 -$9,280,289 +$3,886,811 UL, JPM, MRK, JNJ, MSM 13F-HR 17 Jul 2023, 15:35
Q1 2023 70 $240,430,000 +$27,318,841 -$26,026,803 +$1,292,038 UL, JPM, TXN, MRK, VZ 13F-HR 05 Apr 2023, 16:48
Q4 2022 71 $242,300,000 +$8,751,612 -$10,373,763 -$1,622,151 PFE, UL, XOM, MRK, JPM 13F-HR 05 Jan 2023, 14:43
Q3 2022 77 $215,683,000 +$25,221,411 -$3,815,234 +$21,406,177 PFE, UL, JNJ, XOM, AMGN 13F-HR 06 Oct 2022, 13:18
Q2 2022 71 $210,764,000 +$12,138,777 -$3,893,989 +$8,244,788 PFE, UL, JNJ, VZ, AMGN 13F-HR 08 Jul 2022, 12:56
Q1 2022 70 $219,032,000 +$15,288,561 -$9,576,452 +$5,712,109 CVX, PFE, JNJ, GD, JPM 13F-HR 06 Apr 2022, 11:01
Q4 2021 69 $211,842,000 +$5,677,842 -$4,295,563 +$1,382,279 PFE, JPM, CSCO, TXN, JNJ 13F-HR 06 Jan 2022, 18:17
Q3 2021 68 $198,006,000 +$4,271,756 -$1,524,860 +$2,746,896 PFE, JPM, USB, INTC, TXN 13F-HR 06 Oct 2021, 12:16
Q2 2021 68 $197,229,000 +$6,105,196 -$2,961,529 +$3,143,667 JPM, PFE, TXN, USB, JNJ 13F-HR 06 Jul 2021, 15:53
Q1 2021 69 $188,392,000 +$13,839,747 -$8,482,278 +$5,357,469 JPM, PFE, TXN, USB, JNJ 13F-HR 14 Apr 2021, 12:18
Q4 2020 67 $171,127,000 +$10,220,998 -$3,447,036 +$6,773,962 TXN, PFE, JPM, JNJ, MSM 13F-HR 07 Jan 2021, 13:54
Q3 2020 63 $149,500,000 +$14,357,059 -$9,857,254 +$4,499,805 UPS, PFE, AMGN, TXN, JNJ 13F-HR 07 Oct 2020, 18:00
Q2 2020 60 $142,158,000 +$10,870,826 -$14,444,416 -$3,573,590 PFE, UPS, AMGN, JNJ, MSFT 13F-HR 07 Jul 2020, 15:43
Q1 2020 58 $131,272,000 +$19,985,167 -$26,163,032 -$6,177,865 PFE, JNJ, AMGN, UPS, GILD 13F-HR 21 Apr 2020, 15:29
Q4 2019 62 $169,199,000 +$21,894,797 -$8,839,439 +$13,055,358 PFE, JPM, JNJ, AMGN, CVX 13F-HR 31 Jan 2020, 16:23
Q3 2019 53 $148,583,000 +$18,127,070 -$13,465,493 +$4,661,577 PFE, JNJ, GSK, JPM, AAPL 13F-HR 20 Nov 2019, 12:37
Q2 2019 50 $141,354,000 +$12,347,921 -$5,570,186 +$6,777,735 PFE, JNJ, CSCO, SBUX, GSK 13F-HR 12 Aug 2019, 14:36
Q1 2019 61 $129,547,000 +$18,875,266 -$7,338,448 +$11,536,818 PFE, JNJ, CSCO, GSK, SBUX 13F-HR 07 May 2019, 18:19
Q4 2018 49 $108,360,000 +$12,358,056 -$7,557,548 +$4,800,508 PFE, SBUX, JNJ, PG, AMGN 13F-HR 13 Feb 2019, 17:55
Q3 2018 58 $111,624,000 +$10,068,582 -$2,427,324 +$7,641,258 PFE, JNJ, AAPL, CSCO, AMGN 13F-HR 14 Nov 2018, 17:06
Q2 2018 45 $96,933,000 +$5,153,585 -$8,782,975 -$3,629,390 PFE, JNJ, GSK, RDSB, CVX 13F-HR 13 Aug 2018, 17:23
Q1 2018 44 $100,452,000 +$8,370,999 -$1,706,753 +$6,664,246 CSCO, PFE, JNJ, GSK, AAPL 13F-HR 14 May 2018, 14:02
Q4 2017 44 $96,343,000 $0 $0 $0 JNJ, CSCO, PFE, BA, AAPL 13F-HR 13 Feb 2018, 12:40